Business, energy, technology, markets and global industry news from Business News Today

American Association for Cancer Research

PharmaDeviceNews American Association for Cancer Research
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Alterome Therapeutics schedules first Phase 1 clinical data presentation for pan-KRAS inhibitor ALTA3263

Alterome Therapeutics will reveal first ALTA3263 Phase 1 data in November, testing the safety and early activity of its oral pan-KRAS inhibitor.

Read More
Representative image of live tumour profiling and cytotoxicity testing, illustrating how the Elephas elive platform could expand functional precision oncology beyond immunotherapy into targeted therapy response assessment. Representative image.
Medical Devices & Diagnostics

Can Elephas move beyond immunotherapy? New elive data opens a targeted therapy pathway

Elephas reports early elive data showing cytotoxicity measurement with daraxonrasib, expanding live tumor profiling beyond immunotherapy.

Read More
Pheast Therapeutics’ PHST001 anti-CD24 research highlights a macrophage-directed approach to targeting solid tumors as Phase 1 combination testing advances. Representative image.
Pharma & Biotech

Pheast Therapeutics strengthens PHST001 case with peer-reviewed anti-CD24 cancer research

Pheast Therapeutics’ PHST001 gains peer-reviewed CD24 data as Phase 1 combination cohorts advance. See what the evidence means.

Read More
Tract Bio’s TP101 and stemECHO research targets drug-resistant cancer stem cells through preclinical combination testing and functional precision medicine screening. Representative image.
Pharma & Biotech

TP101 drove near-complete tumor regression in mice. What must Tract Bio prove next?

Tract Bio's AACR posters link TP101 and stemECHO to drug-resistant cancer stem cells, while IND work and clinical validation remain the key hurdles ahead.

Read More